Policy Priorities

Policy and Advocacy Priorities

2023

Structured for Success: Legislative Purpose, Targets, and Focus under PEPFAR vs. International Pandemic Preparedness
Budget & Data Advocacy
Global HIV Advocacy

A Dangerous Precedent: Tennessee Rejects Federal Funds for HIV Prevention
Budget & Data Advocacy
HIV Research and Medication Access

2022

CD4C, CLAW, EANNASO-ATAC-APCASO – Community-led Monitoring – Best practices for strengthening the model
Budget & Data Advocacy

Structured for Success: Centralized Coordinating Authority under PEPFAR vs. International Pandemic Preparedness
Budget & Data Advocacy
Global HIV Advocacy

Structured for Success: Political Will, Power, and Process in the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)
Budget & Data Advocacy
Global HIV Advocacy

MPX Research Gaps: What Remains Unknown
Key and Marginalized Populations

Tackling MPX in Black and Latino Communities
Key and Marginalized Populations

Monkeypox and Meningococcal Disease Outbreaks Signal New Health Threats For Communities Heavily Impacted by HIV And Demand Immediate Action
Key and Marginalized Populations

Blinded by Our Own Data — Recency Testing in PEPFAR
Budget & Data Advocacy
Global HIV Advocacy

2021

A Neglected Population: Transgender Inclusion in National HIV Plans
Key and Marginalized Populations

Current allocations and target apportionment for HIV testing and treatment services for marginalized populations: characterizing PEPFAR investment and strategy
Budget & Data Advocacy
Key and Marginalized Populations

2020

PEPFAR in the Age of COVID-19: The Need for Supplemental Funding
Global HIV Advocacy

ISSUE BRIEF: Violence Crisis Services During Lockdown – PDF
Global HIV Advocacy
Gender Equity & HIV

amfAR Study Shows How White Counties Have Lower Rates of COVID-19 and HIV
COVID-19

Factors Linked to Structural Racism Put Latino Communities at Risk for COVID-19, New Study Says
COVID-19

amfAR Study Shows Disproportionate Impact of COVID-19 on Black Americans
COVID-19

Context Matters – Health Insurance Coverage Is Fundamental to Ending the HIV Epidemic
Ending the HIV Epidemic (U.S.)

2019

Issue Brief: The Expanded Mexico City Policy – Implications for the Global Fund
Gender Equity and HIV
Global HIV Advocacy

Data Watch: Data Accessibility from Global Funders of HIV, TB, and Malaria Programming
Budget & Data Advocacy
Global HIV Advocacy

Context Matters – Ending the HIV Epidemic Among Latinx
Ending the HIV Epidemic (U.S.)

Infographic – Ending the HIV Epidemic Database
Ending the HIV Epidemic (U.S.)

How the Global Fund Improves PEPFAR Investments
Global HIV Advocacy

amfAR Policy Data Used by Congress
Gender Equity and HIV
Global HIV Advocacy

A Global Response to HIV Requires the Global Fund
Global HIV Advocacy

Expanding Access to Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults
HIV Research and Medication Access

New HIV Testing Strategies in PEPFAR COP19: Rollout and Human Rights Concerns
Global HIV Advocacy

Issue Brief – Title X, the Domestic Gag Rule, and the HIV Response
Gender Equity and HIV

INFOGRAPHIC: How Expanded Mexico City Policy Is Disrupting Global HIV Programs
Global HIV Advocacy
Gender Equity and HIV

amfAR’s Statement on President Trump’s Plan to End HIV Transmissions in the US
Ending the HIV Epidemic (U.S.)

Issue Brief: The Effect of the Expanded Mexico City Policy on HIV/AIDS Programming: Evidence from the PEPFAR Implementing Partners Survey
Global HIV Advocacy
Gender Equity and HIV

amfAR’s Medication-Assisted Treatment Analysis Featured in New York Times
Opioid Epidemic & Drug Policy